The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Anti-Asthmatics And COPD Drugs Market From 2026 To 2030?
The anti-asthmatics and COPD drugs market size has observed steady expansion in recent years. This market is projected to grow from $85.08 billion in 2025 to $89.13 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.8%. The increase observed in the historic period is attributable to the rising prevalence of asthma and COPD, increasing levels of smoking and air pollution, limited understanding of preventive therapies, the availability of generic bronchodilators, and the growth in hospital pharmacy networks.
The anti-asthmatics and copd drugs market is anticipated to show significant expansion in the foreseeable future, projected to achieve a size of $111.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is fueled by advancements in biologics and monoclonal antibodies, the integration of artificial intelligence into treatment plans, increasing adoption of digital health solutions, the broadening reach of online pharmacy channels, and the development of targeted therapies for severe COPD. Noteworthy trends for this period encompass personalized asthma management, the rise of telemedicine and remote patient monitoring, the creation of inhalable biologics, a growing preference for combination therapies, and a specific focus on pediatric and geriatric formulations.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What Significant Factors Are Influencing The Anti-Asthmatics And COPD Drugs Market Expansion?
The substantial occurrence of asthmatic conditions is anticipated to fuel the expansion of the anti-asthmatics and COPD drugs market moving forward. Asthma is characterized as a long-term ailment that results in inflammation and swelling within the airways, causing a narrowing of the passages responsible for carrying air from the nose and mouth to the lungs. With an escalation in asthma cases, there has been a notable increase in the identification of new anti-asthmatics and COPD drugs for addressing asthmatic disorders. For instance, in June 2025, according to the Official Statistics, a UK-based government department, the rate of emergency admissions for asthma in adults (19+) climbed by 17% in the financial year ending 2024, compared to the previous year. Consequently, the rising number of asthmatic disorders leads to an enhanced development of novel drugs, which will further propel the asthma drug market.
What Are The Main Segments Within The Anti-Asthmatics And COPD Drugs Market Segment Structure?
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
What Emerging Trends Are Seen In The Anti-Asthmatics And COPD Drugs Market?
Leading companies in the anti-asthmatics and COPD drugs market are concentrating on technological advances, such as next-generation propellant inhalers, to satisfy the growing demand for environmentally friendly and patient-focused respiratory treatments. This next-generation propellant technology replaces conventional hydrofluoroalkane (HFA) propellants with alternatives featuring near-zero Global Warming Potential (GWP), thereby diminishing the carbon footprint of pressurized metered-dose inhalers (pMDIs) while maintaining efficient drug delivery. For instance, in May 2025, AstraZeneca plc, a biopharmaceutical company located in the UK, launched Trixeo Aerosphere, an innovative fixed-dose triple-combination therapy for COPD containing budesonide, glycopyrronium, and formoterol fumarate, now delivered via a next-generation propellant. This specific pMDI ensures bioequivalence to prior formulations, upholds the established safety and efficacy profile, and delivers a 99.9% reduction in GWP compared to traditional propellants. Trixeo Aerosphere supports sustainable healthcare approaches without compromising clinical outcomes, offering an effective, low-carbon-footprint option for patients who require inhaled respiratory therapy.
Who Are The Companies Participating In The Anti-Asthmatics And COPD Drugs Market?
Major companies operating in the anti-asthmatics and copd drugs market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Lupin Limited, Abbott Laboratories, Pfizer, Vectura Group, Bayer, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria.
Get The Full Anti-Asthmatics And COPD Drugs Market Report:
Which Region Is The Leading Market For The Anti-Asthmatics And COPD Drugs Market?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2025. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anti-Asthmatics And COPD Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Anti-Asthmatics And COPD Drugs Market 2026, By The Business Research Company
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Asthma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model